Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
P/E ratio for Ocuphire Pharma, Inc. (OCUP)
P/E ratio as of 2023: -6.51
According to Ocuphire Pharma, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.51. At the end of 2022 the company had a P/E ratio of 3.93.
P/E ratio history for Ocuphire Pharma, Inc. from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.51 |
| 2022 | 3.93 |
| 2021 | -0.98 |
| 2020 | -0.96 |
| 2019 | -0.72 |
| 2018 | -2.13 |
| 2017 | -2.19 |
| 2016 | -3.27 |
| 2015 | -4.56 |
| 2014 | -3194.75 |
| 2013 | -3315.29 |
| 2012 | -2321.33 |
| 2011 | -1496.00 |
| 2010 | 0.00 |
| 2009 | -3138.15 |
| 2008 | -4857.77 |
| 2007 | -12629.92 |
| 2006 | -4882.08 |
| 2005 | -6346.58 |